The overexpression of RCC2 occurred in lung cancer and ovarian cancer, and their sensitivity to drug-induced cell death was altered by RCC2 expression in cancer cells, indicating that RCC2 may function as an effective marker for forecasting chemotherapeutic reaction [10]. The gene discussed is RCC2; the disease is ovarian cancer.